Acylex

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Acylex

Property Description
Active ingredient Aciclovir (INN), Acyclovir (USAN)
Form Tablets, capsules, oral suspension, cream, intravenous infusion, ophthalmic ointment
Pharmacological class Selective antiviral agent; Purine Nucleoside Analogue
General purpose Suppression of viral replication
Origin Synthetic guanine derivative

Acylex is a medication whose core substance is the active ingredient Aciclovir, a synthetic compound chemically defined as a purine nucleoside analogue designated for use as a selective antiviral agent. This medication belongs to the antiviral drug class and functions specifically by targeting and interfering with the reproductive cycle of certain viruses, such as Herpes simplex and Varicella-zoster. The efficacy of Aciclovir is clinically recognized for its specific anti-herpes activity.

Composition and Available Forms of Acylex

The active ingredient, Aciclovir, is a synthetic guanine derivative, which confirms its origin as a chemically manufactured substance rather than a natural one. The composition of Acylex focuses on the therapeutic action of this single-ingredient product, which is often marketed in forms targeted toward specific patient groups, such as adults and pediatric patients requiring systemic treatment.

Aciclovir is used to help relieve the pain and discomfort associated with these infections and facilitates faster healing of the sores. The product is manufactured in a range of dosage forms, including tablets or capsules for oral systemic action, as well as a cream or ophthalmic ointment for topical and localized application. This versatility in pharmaceutical preparations allows the medicine to address viral manifestations either throughout the body or concentrated directly at the site of infection.

Regulatory References

  1. Acyclovir: MedlinePlus Drug Information

What side effects are possible with Acylex?

Possible Side Effects and Safety Information

The safety profile for Aciclovir, the active ingredient in Acylex, is documented in official regulatory sources, classifying possible effects by frequency and the body system affected. These classifications detail the potential for adverse reactions, which range from common and expected events to rare, serious concerns.

Adverse Reaction Classifications

Side effects are grouped by System-Organ Class (SOC) in regulatory documents, with the most commonly documented reactions affecting the Nervous System (e.g., headache, dizziness) and the Gastrointestinal System (e.g., nausea, vomiting, diarrhea).

Frequency Classification Examples of Documented Effects
Common Headache, dizziness, nausea, vomiting, diarrhea, skin rash, pruritus.
Uncommon Urticaria (hives), diffuse hair loss (alopecia).
Rare Anaphylaxis, angioedema, increases in blood urea and creatinine (renal markers).
Very Rare Anemia, leukopenia, hepatitis, jaundice, acute renal failure, confusion, convulsions, coma.

Serious Safety Considerations

Regulatory information explicitly highlights serious adverse reactions that have been documented. These include Acute Renal Failure, which is associated with factors like inadequate hydration during systemic treatment. Furthermore, severe blood disorders, such as Thrombotic Thrombocytopenic Purpura (TTP)/Hemolytic Uremic Syndrome (HUS), are documented as rare occurrences, primarily in severely immunocompromised patients.

Population-Specific Notes

The official safety documents define specific considerations for certain groups. Older adults may be more susceptible to central nervous system (CNS) effects, such as confusion or tremors, due to age-related changes in drug clearance. Patients with pre-existing renal impairment are documented as being at a higher risk of dose-dependent renal toxicity and CNS symptoms. Adequate hydration is a safety restriction explicitly noted in the labeling to help mitigate the risk of renal drug precipitation.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Acylex


Overdose Scope

Element Regulatory Statement
Documented overdose presentations Neurological: Agitation, confusion, hallucinations, lethargy, seizures, and coma. Renal: Acute renal failure, anuria, and elevated serum creatinine and BUN.
Physiological systems affected (as stated in label) Central Nervous System (CNS) and Renal System.
Dose-related or exposure-related factors (if applicable) Risk increases from high intravenous doses, particularly when fluid and electrolyte balance is not monitored, or in patients with pre-existing reduced kidney function.
Population-specific overdose notes (if applicable) Elderly patients are at an increased risk of developing severe CNS effects.
Emergency-response statements (as written in official documents) Contact a Poison Help line or emergency services immediately. Management is symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Overdose Classifications (High-Level)

Classification Detail Regulatory Statement
Severity classification (as defined in official documents) Classified as potentially life-threatening, resulting in acute renal failure, anuria, and coma.
Regulatory basis (EMA / FDA / etc.) Based on the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) documentation.
Overdose-context constraints (as defined in official documents) No specific antidote is known. Management includes monitoring of fluid balance and the potential use of haemodialysis to remove the drug.

Resulting Overdose Structure

Official overdose statements:

  • Overdose manifestations involve severe CNS disturbances, including agitation, hallucinations, and progression to seizures and coma.
  • The life-threatening outcome documented is acute renal failure with anuria, caused by drug precipitation in the renal tubules.
  • Immediate medical attention must be sought for severe signs like collapse, breathing difficulty, or loss of consciousness.
  • Management is symptomatic and supportive, with haemodialysis specified as a means of drug removal and treating resulting anuria.

Connection to the overall overdose profile

Regulatory documents define the Acylex overdose profile by detailing the spectrum of neurological and renal manifestations that result from excessive exposure, specifying the high-risk conditions, such as reduced kidney function and inadequate fluid monitoring. This information mandates the need to seek immediate medical attention when severe, life-threatening symptoms—like seizures, coma, or acute renal failure—are suspected, focusing the required actions on emergency care and supportive procedures like haemodialysis.

Therapeutic Uses of Acylex

What Acylex Treats: Main Uses and Benefits

Acylex is an antiviral medication that is commonly used across conditions presenting with acute episodes caused by the herpes family of viruses. It is primarily applied across domains where additional symptomatic support is needed to address the viral burden associated with conditions like Shingles (Herpes Zoster), Chickenpox, Genital Herpes, and cold sores. The medication is relevant for easing symptom clusters that may become intense or disruptive.

“This medicine is relevant when supportive symptom management is appropriate, particularly during phases when viral symptoms become more noticeable.”

Targeted Symptom Relief and Supportive Benefits

This medication is used to manage symptoms related to physical discomfort, such as pain, burning, itching, and the formation of sores or blisters. When applied appropriately, it supports the patient during difficult episodes by easing distress and supporting the body's natural recovery process. For conditions involving recurrent or episodic manifestations like Genital Herpes, it is applied in clinical settings for the prevention of future outbreaks. Used suppressively, it may assist with managing the frequency of recurrent episodes and provides support that helps maintain a sense of stability.


Brief Note on Symptom Support: This medication may assist with supporting functional stability and contributes to easing the overall symptom load during periods of heightened physical discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Regulatory documents explicitly define which populations can or cannot use Acyclovir (Acylex) based on formal eligibility and contraindications.

Official Eligibility and Non-Eligibility

Classification Population Detail Regulatory Status
Contraindicated Patients with known hypersensitivity or severe allergic reaction to Acyclovir or Valacyclovir, or to any component of the specific formulation. Prohibited
Age-Related Children under 2 years (for some formulations) or under 12 years (for some topical uses). Use not established or Not Recommended
Special Consideration Patients with existing Renal Impairment (kidney disease) or Dehydration. Dose Adjustment Required / Careful Monitoring
Special Consideration Geriatric patients (over 65 years old). Careful Monitoring (due to common age-related decrease in renal function)
Special Consideration Patients with a weakened immune system (e.g., HIV/AIDS) or pre-existing nervous system problems. Special Medical Review (due to increased risk of serious side effects)
Physiological State Pregnancy or Lactation (Breastfeeding). Requires Medical Advice (Use only if benefits outweigh risks; not a formal contraindication)

All individuals must disclose their full health history to their prescriber. Use is generally permitted for most adults and children outside of the formally restricted groups, but specific conditions necessitate medical review and often require dose adjustment and close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented drug-drug and drug-product interactions for Acylex (Acyclovir), strictly based on official regulatory labeling. Acylex is primarily eliminated from the body unchanged in the urine via active renal tubular secretion.

Pharmacokinetic Interactions (Exposure Modification)

Co-administration with other medicines that share or inhibit this renal tubular secretion pathway can alter the concentration of Acylex in the bloodstream.

Interacting Product Regulatory Finding
Probenecid Significantly increases the exposure and half-life of Acyclovir, and reduces its total renal clearance.
Other Drugs Cleared by Active Renal Tubular Secretion Concomitant use may increase the plasma concentrations of Acyclovir due to competitive inhibition of excretion.

Pharmacodynamic and Safety Considerations

Official labeling advises caution regarding certain combinations due to potential effects on the kidney, which are separate from plasma concentration changes.

Interaction Context Constraint and Outcome
Potentially Nephrotoxic Agents Caution is advised when administered concurrently, as this combination may increase the risk of renal dysfunction.

Regulatory documentation establishes that the interaction profile centers on the potential for elevated drug levels and an increased risk of kidney-related effects when used with certain medications.

Mechanism of Action

How Acylex Works

Acylex (acyclovir) works via a highly specific, two-step pharmacodynamic mechanism targeting the viral replication machinery. It functions initially as an inactive prodrug, requiring entry into the host cell. The first and most critical step is selective activation by the viral enzyme thymidine kinase, which is predominantly found within the infected cell. This enzyme phosphorylates Acylex, converting it into its monophosphate form and initiating the molecular cascade. This reliance on a viral-specific enzyme limits the accumulation of the active compound in uninfected cells.

The activated form of the drug is subsequently tri-phosphorylated, enabling it to act as a structural mimic of a natural DNA building block. It directly engages the viral genetic process by acting as a competitive inhibitor of viral DNA polymerase. When incorporated into the growing viral DNA chain, the drug causes immediate chain termination, physically preventing the virus from copying its genetic material. This targeted interference with the core replication process modulates overactive viral signaling and limits the downstream consequences of excessive pathogen activity, which drives the cessation of subsequent viral propagation.

Dosage and Administration Information

Official Administration Guidelines

Acylex (Aciclovir) is available for multiple administration routes, including oral (tablets, capsules, suspension), intravenous (IV) infusion, topical (cream, ophthalmic ointment), and specialized buccal tablets. The method and schedule of use are governed by clinical guidelines to ensure appropriate delivery.

Administration Detail Official Instruction
Dosing Frequency Typically 5 times daily (e.g., every 4 hours, omitting night dose) for acute treatment, or twice daily for suppressive therapy. IV dosing is usually every 8 hours.
Timing Relative to Food Oral forms may be taken with or without food. Taking them with a full glass of water is recommended.
IV Administration IV infusion must be administered slowly over at least one hour; it is not approved for rapid injection or for intramuscular/subcutaneous use.
Special Preparation IV solution must be diluted to a concentration of 7 mg/mL or less. Oral tablets may be dispersed in a minimum of 50 mL of water if swallowing is difficult.

Population-Specific and Procedural Use

Dose adjustment is required for geriatric patients and all patients with impaired renal function (based on Creatinine Clearance) to prevent accumulation; the dosing interval is extended accordingly. Adequate hydration must be maintained, especially during high-dose oral or IV treatment. Treatment for episodic outbreaks should be initiated at the earliest sign or symptom (the prodrome) for optimal results. If a dose is missed, take it as soon as remembered, but skip it if it is almost time for the next scheduled dose to avoid taking a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Acylex

This section provides a transparent overview of the research that has explored the use of Acylex (Aciclovir), describing the types of studies conducted, what they monitored, and where the evidence remains incomplete or uncertain. This information reflects group patterns observed in studies and does not determine whether an individual will respond similarly.


Evidence for Use in Genital Herpes (Episodic and Suppressive Studies)

Researchers have conducted Randomized Controlled Trials (RCTs) to examine the use of Aciclovir during active outbreaks in various groups, including immunocompetent adults. These studies monitored outcomes related to physical discomfort and the time required for lesions to heal fully. Studies reported measurements related to the time for lesions to complete healing were recorded in the observed populations compared to control groups. Additionally, long-term RCTs monitored the frequency of recurrent episodes over periods up to 24 months, where measurements related to the frequency of recurrent episodes were lower in populations receiving continuous therapy compared to control groups.


Evidence for Use in Shingles (Herpes Zoster)

Short-term RCTs and subsequent meta-analyses explored the use of Acylex in treating the acute phase of Shingles, including studies in older adults. Studies monitored outcomes related to acute pain duration and rash healing. Measurements related to the time for new lesion formation to cease and for rashes to complete healing were recorded in the populations studied compared to control groups. Research also monitored the long-term incidence of Postherpetic Neuralgia (PHN). However, findings were mixed across some individual trials regarding this chronic pain outcome, and the research investigating the occurrence of chronic, long-term pain remains a point of variability across studies.


What Remains Unclear and Uncertain in the Research

Evidence quality varies across studies, and data for certain groups, such as pregnant women or individuals with less common co-existing conditions, remain insufficient. Comparative evidence against newer antiviral alternatives is often lacking or heterogeneous in published trials. This evidence highlights what is known, and what is still uncertain about Acylex research.

Key Studies & References

  1. Comparing Prodrugs with Acyclovir for Treating Postherpetic Neuralgia among Herpes Zoster Patients: A Systematic Review and Meta-Analysis
  2. EVIDENCE TABLES AND EVIDENCE-TO-DECISION FRAMEWORKS - WHO Guidelines for the Treatment of Genital Herpes Simplex Virus
  3. LABEL: ACYCLOVIR tablet (FDA Approved Drug Labeling)

Frequently Asked Questions (FAQ)

Common questions about Acylex (FAQ)

Q: What should I do if I forget to take my Acylex dose?

Regulatory documents state that a dose should be taken as soon as it is remembered. If it is almost time for the next scheduled dose, the official guidance indicates the missed dose should be skipped. Patients should not take a double dose to compensate for the missed one.


Q: What are the most common side effects of Acylex?

The official product safety information lists common side effects, which may include mild effects such as headache, dizziness, nausea, vomiting, and diarrhea. Common advice for side effects like headache includes resting and maintaining hydration, but specific management should be discussed with a healthcare professional. Taking the medication with a simple meal or snack is sometimes suggested to help manage nausea.


Q: How long does it take for Acylex to work for a cold sore or outbreak?

Studies and official information suggest that starting Acylex at the earliest sign of an outbreak can optimize results. Clinical evidence indicates the treatment is intended to speed up the healing process and reduce the overall duration of symptoms. For instance, some clinical research noted that healing time may be reduced by approximately one day compared to observed control groups.


Q: Can children take this medication?

Yes, Acylex has established, weight- or age-based dosing schedules for specific viral infections in children, which is reflected in the official prescribing information. The dose and suitability for children should be assessed and determined by a healthcare provider.


Q: What type of virus does Acylex treat?

Acylex, which contains the active ingredient Acyclovir, is a selective antiviral agent that targets viruses in the herpes family. It is officially used for infections caused by the Herpes Simplex Virus (HSV), such as cold sores and genital herpes, and the Varicella-zoster Virus (VZV), which causes shingles and chickenpox.


Q: Can I drink alcohol while taking Acylex?

Official labeling does not list a direct interaction between alcohol and Acyclovir. However, the medication is associated with side effects like dizziness and changes to the nervous system. Patients are often advised to limit alcohol intake when taking any medication that causes these types of central nervous system effects.


Q: If I am pregnant, can I continue to take Acylex?

According to regulatory sources, the use of Acylex during pregnancy is permissible only if a doctor determines that the potential benefit to the mother is greater than any potential risk to the developing baby. Any decision to continue this medication should be made in consultation with a healthcare provider.


Q: What is the typical starting dose for an adult?

The official starting dose of Acylex for an adult will vary significantly depending on the viral infection being treated (e.g., initial episode, recurrent outbreak, or preventative therapy). For this reason, a healthcare provider should determine the appropriate dose for the patient’s specific condition and treatment goal.


Q: Can I crush my Acylex tablet if I can't swallow it?

Regulatory information indicates that Acyclovir is available in an oral liquid form, or suspension, which is usually provided for patients who have trouble swallowing solid tablets. If swallowing the tablet is a concern, patients are encouraged to speak to a pharmacist or doctor about the available liquid form, as manipulating solid tablets may not be approved.

How should Acylex be stored and disposed of?

Storage and Disposal Conditions for Acyclovir Tablets

Acyclovir tablets must be stored at controlled room temperature, typically between 15°C to 25°C (59°F to 77°F). The medicine must be protected from light and moisture and should not be stored in environments where it can freeze.

Packaging and Safety

To maintain stability, the product should be kept in its original container and the container must remain tightly closed. As a mandatory safety measure, the medicine must be kept out of the sight and reach of children.

Disposal Requirements

Expired or unused tablets must be disposed of safely. Official guidance instructs users to ask a pharmacist for disposal advice or to follow governmental protocols for household waste disposal, which often involves mixing the medicine with an undesirable substance and sealing it before placing it in the trash. Medicines must not be thrown away via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Acylex found in:

A-Z Index: